• Markets
  • icon
  • Companies
SPL · ASX

Starpharma Holdings Limited (ASX:SPL)

AU$0.095

 -0.003 (-3.061%)
ASX:Live
23/07/2024 04:10:02 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

SPL Overview

SPL Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About SPL

Telephone

Address

Description

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The firm's programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

SPL Price Chart

Key Stats

Market Cap

AU$40.00M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.09 - 0.43

Trade Value (12mth)

AU$30,910.00

1 week

-4%

1 month

5.49%

YTD

-45.14%

1 year

-77.41%

All time high

2.52

Key Fundamentals

EPS 3 yr Growth

-3.000%

EBITDA Margin

-798.90%

Operating Cashflow

-$14m

Free Cash Flow Return

-29.00%

ROIC

-33.50%

Interest Coverage

N/A

Quick Ratio

3.10

Other Data

Shares on Issue (Fully Dilluted)

411m

HALO Sector

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.39

SPL Announcements

Latest Announcements

Date Announcements

02 July 24

Application for quotation of securities - SPL

×

Application for quotation of securities - SPL

02 July 24

Change in substantial holding

×

Change in substantial holding

01 July 24

Change in Director's Interest Notice - Jeff Davies

×

Change in Director's Interest Notice - Jeff Davies

28 June 24

Change in substantial holding

×

Change in substantial holding

27 June 24

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

27 June 24

Change in Director's Interest Notice - L Cheng

×

Change in Director's Interest Notice - L Cheng

25 June 24

Change in substantial holding

×

Change in substantial holding

21 June 24

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

11 June 24

Notification regarding unquoted securities - SPL

×

Notification regarding unquoted securities - SPL

11 June 24

DEP presentation at SNMMI radiopharmaceuticals conference

×

DEP presentation at SNMMI radiopharmaceuticals conference

04 June 24

DEP irinotecan presentation at ASCO 2024 Annual Meeting

×

DEP irinotecan presentation at ASCO 2024 Annual Meeting

03 June 24

DEP cabazitaxel presentation at ASCO 2024 Annual Meeting

×

DEP cabazitaxel presentation at ASCO 2024 Annual Meeting

30 May 24

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

30 May 24

Change in Director's Interest Notice - Cheryl Maley

×

Change in Director's Interest Notice - Cheryl Maley

27 May 24

Positive final DEP irinotecan Phase 2 clinical trial results

×

Positive final DEP irinotecan Phase 2 clinical trial results

22 May 24

Starpharma Business Update

×

Starpharma Business Update

20 May 24

Investor Webinar Notification - SPL Business Update

×

Investor Webinar Notification - SPL Business Update

16 May 24

Change in substantial holding

×

Change in substantial holding

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

17 April 24

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

16 April 24

Change in Director's Interest Notice - R Basser

×

Change in Director's Interest Notice - R Basser

15 April 24

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

08 April 24

Starpharma and Medicxi Partnership Petalion Therapeutics

×

Starpharma and Medicxi Partnership Petalion Therapeutics

08 April 24

Investor Webinar Notification SPL Medicxi Partnership

×

Investor Webinar Notification SPL Medicxi Partnership

01 March 24

S&P DJI Announces March 2024 Quarterly Rebalance

×

S&P DJI Announces March 2024 Quarterly Rebalance

SPL Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.1 20.1 3.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.2 9.2 4.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.5 -4.6 -11.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.15 0.12 0.08 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.15 0.12 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 82.5 -22.8 -28.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 397 407 409 Lock Lock Lock
Basic m Lock Lock Lock Lock 397 407 409 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 5 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.2 160.4 -37.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 29 26 26 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -87.3 253.3 -35.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 30.0 40.7 41.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 70 59 58 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -28 -23 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.2 17.7 -2.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,542.5 -487.3 -798.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -29 -24 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.8 16.7 -3.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,594.5 -510.4 -839.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -27 -23 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -7 -7 -8 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -20 -16 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.4 18.1 3.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,097.4 -345.0 -532.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -15 -13 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 46 3 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -15 -14 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.1 7.0 -1.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -8.4 -3.0 -4.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 60 50 35 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 73 66 52 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 7 3 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -59 -42 -27 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 11 18 17 Lock Lock Lock
Equity $m Lock Lock Lock Lock 62 48 35 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 63 56 38 Lock Lock Lock
     Growth % Lock Lock Lock Lock 94.4 -11.0 -32.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -26.9 -24.4 -30.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -59.5 -39.8 -49.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -41.5 -27.2 -33.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -31.2 -22.2 -29.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.1 1.8 1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -95.2 -86.2 -77.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.8 5.9 3.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.6 5.7 3.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 85.5 82.3 74.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -142.0 -128.6 -93.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.2 0.6 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.1 1.2 0.6 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 373.2 144.4 225.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,500.6 -500.1 -791.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -36.8 -35.4 -44.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -26.9 -24.4 -30.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.4 1.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 321.2 298.8 595.1 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 1,474.4 634.4 997.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,795.6 933.2 1,593.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 815.5 633.9 1,465.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 980.2 299.3 127.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.39%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

-0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

SPL Shortsell

Frequently Asked Questions

The current share price of Starpharma Holdings Limited (SPL:ASX) is AU$0.095.
The 52-week high share price for Starpharma Holdings Limited (SPL:ASX) is AU$0.43.
The 52-week low share price for Starpharma Holdings Limited (SPL:ASX)? is AU$0.09.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) has a franking level of 0.0%.
Starpharma Holdings Limited (SPL:ASX) is classified in the Healthcare.
The current P/E ratio for Starpharma Holdings Limited (SPL:ASX) is .